You are here

Derin Ven Trombozu Sebebi Olarak Heparine Bağlı Trombositopeni: Diyaliz Hastalarında Fondaparinux Etkinliği

Heparin-induced Thrombocytopenia As A Cause of Deep Venous Thrombosis: Effectiveness of Fondaparinux in Dialysis Patients

Journal Name:

Publication Year:

DOI: 
10.5262/tndt.2010.1001.09

Keywords (Original Language):

Abstract (2. Language): 
A 63-year-old woman with Stage 5 chronic kidney disease presented with severe weakness, nausea, and vomiting. A catheter was inserted to the right femoral vein for hemodialysis. She received low molecular weight heparin (LMWH) (enoxaparine sodyum) during two consecutive hemodialysis sessions. The patient developed swelling of the right leg four days after catheter insertion. Heparinisation with unfractionated heparin was initiated because it was thought the patient had a femoral venous catheterinduced acute deep venous thrombosis. The platelet count decreased to 23 x103/mm3 on the first day of heparin infusion. Re-evaluation of the platelet count records showed that the number of platelets had dropped from 119 x103/mm3 to 80 x103/mm3 after LMWH, but this had gone unnoticed. Heparin was stopped and the patient was given Fondaparinux, a synthetic selective inhibitor of activated factor X, for alternative anticoagulation at a dose of 2.5 mg every other day subcutaenously and later started on peritoneal dialysis. The patient was discharged on warfarin after 20 days. Venous doppler revealed no thrombosis at the right main deep and surface femoral vein on the 32nd day. It seems that the deep venous thrombosis was related to Type II heparin-induced thrombocytopenia with localized vascular injury due to the hemodialysis catheter predisposing to the thrombotic event. In conclusion, heparininduced thrombocytopenia (HIT) can cause deep venous thrombosis, and should not be overlooked in patients with a reduced platelet count on dialysis. Use of Fondaparinux was effective in clearing the thrombosis
Abstract (Original Language): 
Altmış üç yaşındaki, evre 5 kronik böbrek hastası bir kadın hasta ciddi halsizlik, bulantı, kusma yakınması ile başvurdu. Hemodiyaliz için sağ femoral vene kateter yerleştirildi. Takip eden 2 hemodiyaliz seansında düşük molekül ağırlıklı heparin uygulandı. Kateter yerleştirilmesinin 4. gününde sağ bacakta şişme oldu. Katetere bağlı akut derin ven trombozu düşünüldüğü için standart heparin başlanıldı. Heparin infüzyonunun ilk gününde, trombosit sayısı 23 x103/mm3 e düştü. Hastanın kayıtları yeniden gözden geçirildiğinde düşük molekül ağırlıklı heparin kullanımından sonra trombosit sayısının 119 x103/mm3’ten 80 x103/mm3’e düşmüş olduğu; ancak fark edilmediği anlaşıldı. Heparin kesildi ve alternatif olarak Heparin Fondaparinux, aktive faktör X ün bir sentetik selektif inhibitörü, 2,5 mg günaşırı subkutan olarak verildi ve periton diyalizine başlanıldı. Hasta 20 gün sonra varfarin ile taburcu edildi. Otuz ikinci günde yapılan venöz doppler sağ ana derin ve yüzeyel femoral vende tromboz saptamadı. Derin ven trombozu heparin ile ilişkili tip II trombositopeni ile birlikte trombotik olaylara yatkınlık sağlayan hemodiyaliz kateterlerinde dolayı oluşan lokalize vasküler hasarı ile ilişkili görünüyor. Sonuç olarak heparin ile ilişkili trombositopeni derin ven trombozuna neden olabilir ve trombosit sayısı azalan diyaliz hastalarında göz ardı edilmemelidir. Fondaparinux trombozu temizlemede etkindir.

REFERENCES

References: 

1. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf
M, Meyer D: Platelet factor 4 complexed to heparin is the target
for antibodies generated in heparin induced thrombocytopenia.
Thromb Haemost 1992; 68(1): 95-96
2. Yamamoto S, Koide M, Mastsuo M, Suzuki S, Ohtaka M, Saika
S, Matsuo T: Heparin-induced thrombocytopenia in hemodialysis
patients. Am J Kidney Dis 1996; 28: 82-85
3. Finazzi G, Remuzzi G: Heparin induced thrombocytopeniabackground
and implication for haemodialysis. Nephrol Dial
Transplant 1996; 11: 2120-2122
4. Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia:
recognition, treatment, and prevention: the Seventh ACCP
Conference on Antithrombotic and Thrombolytic Therapy. Chest
2004 ;126(3 Suppl):311-337
5. Efird LE, Kockler, DR: Fondaparinux for thromboembolic
treatment and prophylaxis of heparin-induced thrombocytopenia.
Ann Pharmacother 2006;40:1383–1387
6. Harenberg J, Jorg I, Fenyvesi, T: Treatment of heparininduced
thrombocytopenia with fondaparinux. Haematologica
2004;89:1017–1018
7. O’Shea SI, Ortel TL, Kovalik EC: Alternation methods of
anticoagulation for dialysis-dependent patients with heparin induced
thrombocytopenia. Semin Dial 2003; 16(1): 61-67
8. Haase M, Bellomo R, Rocktaeschel J, Ziemer S, Kiesewetter H,
Morgera S, Neumayer HH: Use of fondaparinux (ARIXTRA)
in a dialysis patient with symptomatic heparin-induced
thrombocytopenia type II. Nephrol Dial Transplant 2005; 20(2):444-
446
9. Trottier SJ, Veremakis C, O’Brien J, Auer AI: Femoral deep vein
thrombosis associated with central venous catheterization: results
from a prospective, randomized trial. Crit Care Med 1995; 23:52-
59
10. Fadel FI, Mooty HNA, Bazaraa HM, Sabr SM: Central venous
catheters as a vascular access modality for pediatric hemodialysis.
Int Urol Nephrol 2008; 40:489-496
11. Allen AW, Megargell JL, Brown DB, Lynch FC, Singh H, Singh Y,
Waybill PN: Venous thrombosis associated with the placement of
peripherally inserted central catheters. J Vasc Interv Radiol 2000;
11:1309-1314

Thank you for copying data from http://www.arastirmax.com